NCT06634836Withdrawn
Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
In-trial Qualitative Interviews to Explore the Impact of Gene Therapy in Hemophilia A & B
Source: ClinicalTrials.gov · Last updated 29 Aug 2025
Brief summary (registry, in English)
The purpose of this study is to learn about experiences of patients with hemophilia A and B after taking gene therapy. The experiences of patients will be studied through online interviews. This study is seeking participants who are: * part of the Pfizer's gene therapy clinical studies or * in the long-term follow up for these clinical programs. Participants will have one study visit at the clinic and one online interview. The planned duration for each participant will be 1 to 2 months. This covers the time from entering the study to end of the online interview.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 1 Oct 2024
- Start date
- 17 Mar 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Pfizer
- Diseases
- Haemophilia
- NCT number
- NCT06634836
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -No exclusion criteria
Who the study is looking for
- Participation in the Pfizer's gene therapy clinical trials for Hemophilia A or B .
- Participants will be one year or more post-gene therapy
- Participants will be willing to provide written consent and will be willing to comply with the study requirements
Age in the registry: 18 years to 85 years · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.